Investors

Edesa Biotech – Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. We have multiple late-stage product candidates in our development pipeline in the fields of  medical dermatology and respiratory diseases.

In dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody, as a therapy for vitiligo,  a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play both a key role in the disease and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. We are currently recruiting for a Phase 2 study of EB06 in patients with moderate-to-severe non-segmental vitiligo. Our derm program also includes daniluromer, a Phase 3-ready asset developed for use as a potential therapy for Allergic Contact Dermatitis, a common occupational skin condition.

Our most advanced respiratory drug candidate is paridiprubart. Paridiprubart represents a new class of therapies called Host Directed Therapeutics (HDTs) that are designed to modulate the body’s own immune response when confronted with infectious diseases or even chemical agents. See Phase 3 results.  Paridiprubart is also being evaluated in a U.S. government-funded Phase 2 platform study of HDTs. We have also been awarded Canadian government funding to support this development program.